190957-22-3

Basic information

• Product Name: (R)-4-(hydroxyMethyl)-1-((R)-1-phenylethyl)pyrrolidin-2-one
• Synonyms: (R)-4-(hydroxyMethyl)-1-((R)-1-phenylethyl)pyrrolidin-2-one;(4R)-4-(hydroxymethyl)-1-[(1R)-1-phenylethyl]pyrrolidin-2-one
• CAS NO: 190957-22-3
• Molecular Formula: C₁₃H₁₇NO₂
• Molecular Weight: 219.27958
• EINECS: -0
• Mol File: 190957-22-3.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R)-4-(hydroxyMethyl)-1-((R)-1-phenylethyl)pyrrolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-4-(hydroxyMethyl)-1-((R)-1-phenylethyl)pyrrolidin-2-one(190957-22-3)
• EPA Substance Registry System: (R)-4-(hydroxyMethyl)-1-((R)-1-phenylethyl)pyrrolidin-2-one(190957-22-3)

Safety Data

• Hazardous Substances Data: 190957-22-3(Hazardous Substances Data)

Usage

General Description

The chemical compound "(R)-4-(hydroxyMethyl)-1-((R)-1-phenylethyl)pyrrolidin-2-one" is a chiral molecule with a pyrrolidinone core structure. It contains a hydroxymethyl group and a phenylethyl group, making it suitable for use in pharmaceuticals and as a building block for organic synthesis. The chiral nature of the molecule means that it exists as two enantiomers, or mirror-image forms, with the prefix "(R)" indicating the absolute configuration of the compound. This chemical has the potential for various applications in drug development and as a research tool in the field of organic chemistry.

Upstream product

• 99735-43-0 (3R)-1-((R)-1-phenylethyl)-5-oxo-3-pyrrolidinecarboxylic acid 
• 252051-12-0 (4R,1'R)-[1-(1'-phenylethyl)-2-oxopyrrolidin-4-yl]carboxaldehyde 

Downstream Products

• 252051-16-4 (3S,1'S)-1-(1'-phenylethyl)-3-naphthylaminomethylpyrrolidine 
• 1292289-46-3 (4S)-4-(aminomethyl)pyrrolidin-2-one 
• 1319736-81-6 (R)-4-(tert-butyl-dimethyl-silanyloxymethyl)-3,3-dimethyl-1-((R)-1-phenyl-ethyl)pyrrolidine-2-one 
• 1319736-82-7 (3R,4R)-4-(tert-butyl-dimethyl-silanyloxymethyl)-3-methyl-1-((R)-1-phenyl-ethyl)pyrrolidine-2-one 
• 1319737-91-1 (R)-4-((7-(1,1-dioxo-hexahydro-1λ6-thiopyran-4-yloxy-3-methoxy-phenyl)-1,6-naphthyridine-5-yloxy)methyl)pyrrolidine-2-one 
• 1319737-93-3 (R)-4-{7-[4-(tetrahydro-pyran-4-yloxy)-3-trifluoromethyl-phenyl]-[1,6]naphthyridine-5-yloxymethyl}pyrrolidine-2-one 
• 1319738-00-5 (S)-4-((7-(3,4,5-trimethoxyphenyl)-1,6-naphthyridine-5-ylamino)methyl)pyrrolidine-2-one 
• 1319737-92-2 (R)-4-((7-(4-hydroxy-3-methoxyphenyl)-1,6-naphthyridine-5-yloxy)methyl)pyrrolidine-2-one 
• 1319738-03-8 (R)-4-{7-[3-methoxy-4-(tetrahydro-pyran-4-yloxy)phenyl]-[1,6]naphthyridine-5-yloxymethyl}pyrrolidine-2-one 
• 1319738-10-7 (R)-4-((7-(3,4-dimethoxyphenyl)-1,6-naphthyridine-5-yloxy)methyl)pyrrolidine-2-one 
• 1319738-12-9 (R)-4-[7-(3-Fluoro-4-isopropoxy-phenyl)-[1,6]naphthyridine-5-yloxy-methyl]-pyrrolidine-2-one 
• 1165450-70-3 (R)-4-(hydroxymethyl)pyrrolidine-2-one 
• 1319736-72-5 C₂₁H₁₆Cl₄N₂O₃ 
• 252051-12-0 (4R,1'R)-[1-(1'-phenylethyl)-2-oxopyrrolidin-4-yl]carboxaldehyde 

Relevant articles and documents

SUBSTITUTED QUINOLINES AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted quinolines of formula (1) wherein R1 is a linear or branched C1-6-alkyl, wherein R1 may optionally be substituted by R3 which is selected from the group consisting of a three-, four-, five-, six- or seven-membered cycloalkl; a five-, six- or seven-membered, saturated heterocycle comprising one, two or three heteroatoms each independently selected from the group consisting of N, S and O; and a five- or six-membered heteroaryl comprising one, two or three heteroatoms each independently selected from the group consisting of N, S and O; wherein R3 may optionally be substituted further substituted as defined in claim 1 and wherein R2 is selected from the group consisting of halogen, phenyl, a five- or six-membered monocyclic heteroaryl comprising one, two or three heteroatoms each independently selected from the group consisting of N, S and O; a bicyclic, nine-, ten- or eleven-membered, either aromatic or non-aromatic, but not fully saturated heterocycle comprising one, two, three or four heteroatoms each independently selected from the group consisting of N, S and O; wherein R2 may optionally be further substituted as defined in claim 1, and their use in the preparation of medicaments for the treatment of disease such as asthma, COPD, allergic rhinitis, allergic dermatitis and rheumatoid arthritis.

SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 is selected from among —O—R3 or —NR3R4,R3 is C1-6-alkyl which is substituted by R5 and R6,R5 is selected from hydrogen, branched or linear C1-6-alkyl, C2-6-alkenyl, —C1-6-alkylen-O—C1-3-alkyl, C1-3-haloalkyl,R6 is ring X wherein n is either 0 or 1, and is a either a single or a double bond andwherein A, B, D and E are each independently from one another selected from CH2, CH, C, N, NH, O or S and wherein ring X is attached to the molecule either via position A, B, D or E, wherein said ring X may optionally be further substituted by one, two or three residues each selected individually from the group consisting of -oxo, hydroxy, —C1-3-alkyl, —C1-3-haloalkyl, —O—C1-3-alkyl, —C1-3-alkanol and halogen,and wherein R4, R2, R7, R8, R9, R10, R11 and Q may have the meanings as given in claim 1, as well as pharmaceutical compositions containing these compounds.

SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS

The invention relates to new substituted naphthyridines of formula (1), as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 is selected from among -O-R3 or -NR3R4, R3 is C1-6-alkyl which is substituted by R5 and R6 R5 is selected from hydrogen, branched or linear C1-6-alkyl, C2-6-alkenyl, -C1-6-alkylen-O-C1-3-alkyl, C1-3-haloalkyl, R6 is ring X wherein n is either 0 or 1, and Formula (I) is a either a single or a double bond and wherein A, B, D and E are each independently from one another selected from CH2, CH, C, N, NH, O or S and wherein ring X is attached to the molecule either via position A, B, D or E, wherein said ring X may optionally be further substituted by one, two or three residues each selected individually from the group consisting of -oxo, hydroxy, -C1-3-alkyl, -C1-3-haloalkyl, -O-C1-3-alkyl, -C1-3-alkanol and halogen, and wherein R4, R2, R7, R8, R9, R10, R11 and Q may have the meanings as given in claim 1, as well as pharmaceutical compositions containing these compounds.